LANCET ONCOL - The lancet oncology
Publications
- 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Lin, Y., Qiu, L., Usmani, S., Joo, C. W., Costa, L., Derman, B., Du, J., Einsele, H., Fernandez de Larrea, C., Hajek, R., Ho, P. J., Kastritis, E., Martinez-Lopez, J., Mateos, M-V., Mikhael, J., Moreau, P., Nagarajan, C., Nooka, A., O'Dwyer, M., Schjesvold, F., Sidana, S., van de Donk, N. W., Weisel, K., Zweegman, S., Raje, N., Otero, P. R., Anderson, L. D., Kumar, S., Martin, T. & International Myeloma Working Group, 08.2024, In: LANCET ONCOL. 25, 8, p. e374-e387Research output: SCORING: Contribution to journal › Guideline, recommendation, statement › Research › peer-review
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
Corbacioglu, S., Lode, H., Ellinger, S., Zeman, F., Suttorp, M., Escherich, G., Bochennek, K., Gruhn, B., Lang, P., Rohde, M., Debatin, K. M., Steinbach, D., Beilken, A., Ladenstein, R., Spachtholz, R., Heiss, P., Hellwig, D., Tröger, A., Koller, M., Menhart, K., Riemenschneider, M. J., Zoubaa, S., Kietz, S., Jakob, M., Sommer, G., Heise, T., Hundsdörfer, P., Kühnle, I., Dilloo, D., Schönberger, S., Schwabe, G., von Luettichau, I., Graf, N., Schlegel, P-G., Frühwald, M., Jorch, N., Paulussen, M., Schneider, D. T., Metzler, M., Leipold, A., Nathrath, M., Imschweiler, T., Christiansen, H., Schmid, I., Crazzolara, R., Niktoreh, N., Cario, G., Faber, J., Demmert, M., Babor, F., Fröhlich, B., Bielack, S., Bernig, T., Greil, J., Eggert, A., Simon, T. & Foell, J., 07.2024, In: LANCET ONCOL. 25, 7, p. 922-932 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Rodriguez-Otero, P., Usmani, S., Cohen, A. D., van de Donk, N. W. C. J., Leleu, X., Pérez-Larraya, J. G., Manier, S., Nooka, A. K., Mateos, M. V., Einsele, H., Minnema, M., Cavo, M., Derman, B. A., Puig, N., Gay, F., Ho, P. J., Chng, W-J., Kastritis, E., Gahrton, G., Weisel, K., Nagarajan, C., Schjesvold, F., Mikhael, J., Costa, L., Raje, N. S., Zamagni, E., Hájek, R., Weinhold, N., Yong, K., Ye, J. C., Sidhana, S., Merlini, G., Martin, T., Lin, Y., Chari, A., Popat, R., Kaufman, J. L. & International Myeloma Working Group, 05.2024, In: LANCET ONCOL. 25, 5, p. e205-e216Research output: SCORING: Contribution to journal › SCORING: Review article › Research
- 2023
Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine
Salek, M., Mueller, A., Alanbousi, I., Cepowska, Z., Dutkiewicz, M., Earl, J., Evseev, D., Kizyma, R., Kliuchkivska, K., Kolodrubiec, J., Matczak, K., Nogovitsyna, Y., Oszer, A., Pogorelyy, M., Raciborska, A., Rasul, S., Sokolowski, I., Sopilnyak, A., Vinitsky, A., Wlodarski, M. W., Wobst, N., Yakimkova, T., Rodriguez-Galindo, C., Wise, P. H., Mlynarski, W., Agulnik, A. & SAFER Ukraine Collaborative, 12.2023, In: LANCET ONCOL. 24, 12, p. 1315-1318 4 p.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups
Karschnia, P., Smits, M., Reifenberger, G., Le Rhun, E., Ellingson, B. M., Galldiks, N., Kim, M. M., Huse, J. T., Schnell, O., Harter, P. N., Mohme, M., von Baumgarten, L., Albert, N. L., Huang, R. Y., Mehta, M. P., van den Bent, M., Weller, M., Vogelbaum, M. A., Chang, S. M., Berger, M. S., Tonn, J-C. & Expert Rater Panel, 11.2023, In: LANCET ONCOL. 24, 11, p. e438-e450Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Rha, S. Y., Oh, D-Y., Yañez, P., Bai, Y., Ryu, M-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K-K., Fernández, M. G., Li, J., Lowery, M. A., Çil, T., Cruz, F. M., Qin, S., Luo, S., Pan, H., Wainberg, Z. A., Yin, L., Bordia, S., Bhagia, P., Wyrwicz, L. S. & KEYNOTE-859 investigators, 11.2023, In: LANCET ONCOL. 24, 11, p. 1181-1195 15 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., Weisel, K. C., Badros, A. Z., Beksac, M., Hillengass, J., Mohty, M., Ho, P. J., Ntanasis-Stathopoulos, I., Mateos, M-V., Richardson, P., Blade, J., Moreau, P., San-Miguel, J., Munshi, N., Rajkumar, S. V., Durie, B. G. M., Ludwig, H., Terpos, E. & International Myeloma Working Group, 07.2023, In: LANCET ONCOL. 24, 7, p. e293-e311Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Ludwig, H., Terpos, E., van de Donk, N., Mateos, M-V., Moreau, P., Dimopoulos, M-A., Delforge, M., Rodriguez-Otero, P., San-Miguel, J., Yong, K., Gay, F., Einsele, H., Mina, R., Caers, J., Driessen, C., Musto, P., Zweegman, S., Engelhardt, M., Cook, G., Weisel, K., Broijl, A., Beksac, M., Bila, J., Schjesvold, F., Cavo, M., Hajek, R., Touzeau, C., Boccadoro, M. & Sonneveld, P., 06.2023, In: LANCET ONCOL. 24, 6, p. e255-e269Research output: SCORING: Contribution to journal › SCORING: Review article › Research
- 2022
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE
Otth, M., Brack, E., Kearns, P. R., Kozhaeva, O., Ocokoljic, M., Schoot, R. A., Vassal, G. & Essential Medicines Group, 12.2022, In: LANCET ONCOL. 23, 12, p. 1537-1546 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Nitz, U., Gluz, O., Graeser, M., Christgen, M., Kuemmel, S., Grischke, E-M., Braun, M., Augustin, D., Potenberg, J., Krauss, K., Schumacher, C., Forstbauer, H., Reimer, T., Stefek, A., Fischer, H. H., Pelz, E., Zu Eulenburg, C., Kates, R., Wuerstlein, R., Kreipe, H. H., Harbeck, N. & WSG-ADAPT investigators, 05.2022, In: LANCET ONCOL. 23, 5, p. 625-635 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y. F. L., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., Campone, M., Fasolo, A., Lopez-Martin, J. A., Kim, T. M., Mason, W. P., Hofheinz, R-D., Blay, J-Y., Cho, D. C., Gazzah, A., Pouessel, D., Yachnin, J., Boran, A., Burgess, P., Ilankumaran, P., Gasal, E. & Subbiah, V., 01.2022, In: LANCET ONCOL. 23, 1, p. 53-64 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Saad, F., Efstathiou, E., Attard, G., Flaig, T. W., Franke, F., Goodman, O. B., Oudard, S., Steuber, T., Suzuki, H., Wu, D., Yeruva, K., De Porre, P., Brookman-May, S., Li, S., Li, J., Thomas, S., Bevans, K. B., Mundle, S. D., McCarthy, S. A., Rathkopf, D. E. & ACIS Investigators, 11.2021, In: LANCET ONCOL. 22, 11, p. 1541-1559 19 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Tromp, B., Delioukina, M., Vermeulen, J. & Usmani, S. Z., 11.2021, In: LANCET ONCOL. 22, 11, p. 1582-1596 15 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
COVIDSurg Collaborative, 11.2021, In: LANCET ONCOL. 22, 11, p. 1507-1517 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Vindeløv, S. D., Chen, M., Harris, J. R., Smith, M., Nicacio, L. V., Teng, M. S. L., Laenen, A., Rangwala, R., Manso, L., Mirza, M., Monk, B. J., Vergote, I. & innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators, 05.2021, In: LANCET ONCOL. 22, 5, p. 609-619 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
Guigay, J., Aupérin, A., Fayette, J., Saada-Bouzid, E., Lafond, C., Taberna, M., Geoffrois, L., Martin, L., Capitain, O., Cupissol, D., Castanie, H., Vansteene, D., Schafhausen, P., Johnson, A., Even, C., Sire, C., Duplomb, S., Evrard, C., Delord, J-P., Laguerre, B., Zanetta, S., Chevassus-Clément, C., Fraslin, A., Louat, F., Sinigaglia, L., Keilholz, U., Bourhis, J., Mesia, R. & GORTEC, 04.2021, In: LANCET ONCOL. 22, 4, p. 463-475 13 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Winer, E. P., Lipatov, O., Im, S-A., Goncalves, A., Muñoz-Couselo, E., Lee, K. S., Schmid, P., Tamura, K., Testa, L., Witzel, I., Ohtani, S., Turner, N., Zambelli, S., Harbeck, N., Andre, F., Dent, R., Zhou, X., Karantza, V., Mejia, J., Cortes, J. & KEYNOTE-119 investigators, 04.2021, In: LANCET ONCOL. 22, 4, p. 499-511 13 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Moreau, P., Kumar, S. K., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, B. G. M., Facon, T., Jurczyszyn, A., Sidana, S., Raje, N., van de Donk, N., Lonial, S., Cavo, M., Kristinsson, S. Y., Lentzsch, S., Hajek, R., Anderson, K. C., João, C., Einsele, H., Sonneveld, P., Engelhardt, M., Fonseca, R., Vangsted, A., Weisel, K., Baz, R., Hungria, V., Berdeja, J. G., Leal da Costa, F., Maiolino, A., Waage, A., Vesole, D. H., Ocio, E. M., Quach, H., Driessen, C., Bladé, J., Leleu, X., Riva, E., Bergsagel, P. L., Hou, J., Chng, W. J., Mellqvist, U-H., Dytfeld, D., Harousseau, J-L., Goldschmidt, H., Laubach, J., Munshi, N. C., Gay, F., Beksac, M., Costa, L. J., Kaiser, M., Hari, P., Boccadoro, M., Usmani, S. Z., Zweegman, S., Holstein, S., Harrison, S., Nahi, H., Cook, G., Mateos, M-V., Rajkumar, S. V., Dimopoulos, M. A. & Richardson, P. G., 03.2021, In: LANCET ONCOL. 22, 3, p. e105-e118Research output: SCORING: Contribution to journal › SCORING: Review article › Research
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
Borchmann, P., Plütschow, A., Kobe, C., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Sökler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T. V., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Hüttmann, A., Wilhelm, M., Zijlstra, J. M., Moccia, A., Kuhnert, G., Bröckelmann, P. J., von Tresckow, B., Fuchs, M., Klimm, B., Rosenwald, A., Eich, H., Baues, C., Marnitz, S., Hallek, M., Diehl, V., Dietlein, M. & Engert, A., 02.2021, In: LANCET ONCOL. 22, 2, p. 223-234 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2020
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Subbiah, V., Lassen, U., Élez, E., Italiano, A., Curigliano, G., Javle, M., de Braud, F., Prager, G. W., Greil, R., Stein, A., Fasolo, A., Schellens, J. H. M., Wen, P. Y., Viele, K., Boran, A. D., Gasal, E., Burgess, P., Ilankumaran, P. & Wainberg, Z. A., 09.2020, In: LANCET ONCOL. 21, 9, p. 1234-1243 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Pfisterer, J., Shannon, C. M., Baumann, K., Rau, J., Harter, P., Joly, F., Sehouli, J., Canzler, U., Schmalfeldt, B., Dean, A. P., Hein, A., Zeimet, A. G., Hanker, L. C., Petit, T., Marmé, F., El-Balat, A., Glasspool, R., de Gregorio, N., Mahner, S., Meniawy, T. M., Park-Simon, T-W., Mouret-Reynier, M-A., Costan, C., Meier, W., Reinthaller, A., Goh, J. C., L'Haridon, T., Baron Hay, S., Kommoss, S., du Bois, A., Kurtz, J-E. & AGO-OVAR 2.21/ENGOT-ov 18 Investigators, 05.2020, In: LANCET ONCOL. 21, 5, p. 699-709 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Swain, S. M., Miles, D., Kim, S-B., Im, Y-H., Im, S-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., Clark, E., Knott, A., Restuccia, E., Benyunes, M. C., Cortés, J. & CLEOPATRA study group, 04.2020, In: LANCET ONCOL. 21, 4, p. 519-530 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Cerebrospinal fluid evaluation in adult patients with medulloblastoma
von Bueren, A. O., Hagel, C. & Rutkowski, S., 03.2020, In: LANCET ONCOL. 21, 3, p. e120Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A-O., Callander, N., Lendvai, N., Sborov, D., Suvannasankha, A., Weisel, K., Karlin, L., Libby, E., Arnulf, B., Facon, T., Hulin, C., Kortüm, K. M., Rodríguez-Otero, P., Usmani, S. Z., Hari, P., Baz, R., Quach, H., Moreau, P., Voorhees, P. M., Gupta, I., Hoos, A., Zhi, E., Baron, J., Piontek, T., Lewis, E., Jewell, R. C., Dettman, E. J., Popat, R., Esposti, S. D., Opalinska, J., Richardson, P. & Cohen, A. D., 02.2020, In: LANCET ONCOL. 21, 2, p. 207-221 15 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., San Miguel, J., Sunami, K., O'Gorman, P., Sonneveld, P., Robak, P., Semochkin, S., Schey, S., Yu, X., Doerr, T., Bensmaine, A., Biyukov, T., Peluso, T., Zaki, M., Anderson, K., Dimopoulos, M. & OPTIMISMM trial investigators, 06.2019, In: LANCET ONCOL. 20, 6, p. 781-794 14 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group
Hoeben, B. A., Carrie, C., Timmermann, B., Mandeville, H. C., Gandola, L., Dieckmann, K., Ramos Albiac, M., Magelssen, H., Lassen-Ramshad, Y., Ondrová, B., Ajithkumar, T., Alapetite, C., Balgobind, B. V., Bolle, S., Cameron, A. L., Davila Fajardo, R., Dietzsch, S., Dumont Lecomte, D., van den Heuvel-Eibrink, M. M., Kortmann, R. D., Laprie, A., Melchior, P., Padovani, L., Rombi, B., Scarzello, G., Schwarz, R., Seiersen, K., Seravalli, E., Thorp, N., Whitfield, G. A., Boterberg, T. & Janssens, G. O., 03.2019, In: LANCET ONCOL. 20, 3, p. e155-e166Research output: SCORING: Contribution to journal › SCORING: Review article › Research
- 2018
Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
Goschzik, T., Schwalbe, E. C., Hicks, D., Smith, A., Zur Muehlen, A., Figarella-Branger, D., Doz, F., Rutkowski, S., Lannering, B., Pietsch, T. & Clifford, S. C., 12.2018, In: LANCET ONCOL. 19, 12, p. 1602-1616 15 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group
Rutkowski, S., Modena, P., Williamson, D., Kerl, K., Nysom, K., Pizer, B., Bartels, U., Puget, S., Doz, F., Michalski, A., von Hoff, K., Chevignard, M., Avula, S., Murray, M. J., Schönberger, S., Czech, T., Schouten-van Meeteren, A. Y. N., Kordes, U., Kramm, C. M., van Vuurden, D. G., Hulleman, E., Janssens, G. O., Solanki, G. A., van Veelen, M-L. C., Thomale, U., Schuhmann, M. U., Jones, C., Giangaspero, F., Figarella-Branger, D., Pietsch, T., Clifford, S. C., Pfister, S. M. & Van Gool, S. W., 08.2018, In: LANCET ONCOL. 19, 8, p. e419-e428Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Moreau, P., Mateos, M-V., Berenson, J. R., Weisel, K., Lazzaro, A., Song, K., Dimopoulos, M. A., Huang, M., Zahlten-Kumeli, A. & Stewart, A. K., 07.2018, In: LANCET ONCOL. 19, 7, p. 953-964 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
Waszak, S. M., Northcott, P. A., Buchhalter, I., Robinson, G. W., Sutter, C., Groebner, S., Grund, K. B., Brugières, L., Jones, D. T. W., Pajtler, K. W., Morrissy, A. S., Kool, M., Sturm, D., Chavez, L., Ernst, A., Brabetz, S., Hain, M., Zichner, T., Segura-Wang, M., Weischenfeldt, J., Rausch, T., Mardin, B. R., Zhou, X., Baciu, C., Lawerenz, C., Chan, J. A., Varlet, P., Guerrini-Rousseau, L., Fults, D. W., Grajkowska, W., Hauser, P., Jabado, N., Ra, Y-S., Zitterbart, K., Shringarpure, S. S., De La Vega, F. M., Bustamante, C. D., Ng, H-K., Perry, A., MacDonald, T. J., Hernáiz Driever, P., Bendel, A. E., Bowers, D. C., McCowage, G., Chintagumpala, M. M., Cohn, R., Hassall, T., Fleischhack, G., Eggen, T., Wesenberg, F., Feychting, M., Lannering, B., Schüz, J., Johansen, C., Andersen, T. V., Röösli, M., Kuehni, C. E., Grotzer, M., Kjaerheim, K., Monoranu, C. M., Archer, T. C., Duke, E., Pomeroy, S. L., Shelagh, R., Frank, S., Sumerauer, D., Scheurlen, W., Ryzhova, M. V., Milde, T., Kratz, C. P., Samuel, D., Zhang, J., Solomon, D. A., Marra, M., Eils, R., Bartram, C. R., von Hoff, K., Rutkowski, S., Ramaswamy, V., Gilbertson, R. J., Korshunov, A., Taylor, M. D., Lichter, P., Malkin, D., Gajjar, A., Korbel, J. O. & Pfister, S. M., 06.2018, In: LANCET ONCOL. 19, 6, p. 785-798 14 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W-J., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., Weisel, K., Hungria, V., Minuk, L., Feng, S., Zahlten-Kumeli, A., Kimball, A. S. & Moreau, P., 10.2017, In: LANCET ONCOL. 18, 10, p. 1327-1337 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study
Wolthers, B. O., Frandsen, T. L., Baruchel, A., Attarbaschi, A., Barzilai, S., Colombini, A., Escherich, G., Grell, K., Inaba, H., Kovacs, G., Liang, D-C., Mateos, M., Mondelaers, V., Möricke, A., Ociepa, T., Samarasinghe, S., Silverman, L. B., van der Sluis, I. M., Stanulla, M., Vrooman, L. M., Yano, M., Zapotocka, E., Schmiegelow, K. & Ponte di Legno toxicity working group, 09.2017, In: LANCET ONCOL. 18, 9, p. 1238-1248 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Refining medulloblastoma subgroups
Juhnke, B-O., Mynarek, M. & Rutkowski, S., 07.2017, In: LANCET ONCOL. 18, 7, p. 847-848 2 p.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
Sahm, F., Schrimpf, D., Stichel, D., Jones, D. T. W., Hielscher, T., Schefzyk, S., Okonechnikov, K., Koelsche, C., Reuss, D. E., Capper, D., Sturm, D., Wirsching, H-G., Berghoff, A. S., Baumgarten, P., Kratz, A., Huang, K., Wefers, A. K., Hovestadt, V., Sill, M., Ellis, H. P., Kurian, K. M., Okuducu, A. F., Jungk, C., Drueschler, K., Schick, M., Bewerunge-Hudler, M., Mawrin, C., Seiz-Rosenhagen, M., Ketter, R., Simon, M., Westphal, M., Lamszus, K., Becker, A., Koch, A., Schittenhelm, J., Rushing, E. J., Collins, V. P., Brehmer, S., Chavez, L., Platten, M., Hänggi, D., Unterberg, A., Paulus, W., Wick, W., Pfister, S. M., Mittelbronn, M., Preusser, M., Herold-Mende, C., Weller, M. & von Deimling, A., 05.2017, In: LANCET ONCOL. 18, 5, p. 682-694 13 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Al-Batran, S-E., Hofheinz, R. D., Pauligk, C., Kopp, H-G., Haag, G. M., Luley, K. B., Meiler, J., Homann, N., Lorenzen, S., Schmalenberg, H., Probst, S., Koenigsmann, M., Egger, M., Prasnikar, N., Caca, K., Trojan, J., Martens, U. M., Block, A., Fischbach, W., Mahlberg, R., Clemens, M., Illerhaus, G., Zirlik, K., Behringer, D. M., Schmiegel, W., Pohl, M., Heike, M., Ronellenfitsch, U., Schuler, M., Bechstein, W. O., Königsrainer, A., Gaiser, T., Schirmacher, P., Hozaeel, W., Reichart, A., Goetze, T. O., Sievert, M., Jäger, E., Mönig, S. & Tannapfel, A., 12.2016, In: LANCET ONCOL. 17, 12, p. 1697-1708 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis
Gharahkhani, P., Fitzgerald, R. C., Vaughan, T. L., Palles, C., Gockel, I., Tomlinson, I., Buas, M. F., May, A., Gerges, C., Anders, M., Becker, J., Kreuser, N., Noder, T., Venerito, M., Veits, L., Schmidt, T., Manner, H., Schmidt, C., Hess, T., Böhmer, A. C., Izbicki, J. R., Hölscher, A. H., Lang, H., Lorenz, D., Schumacher, B., Hackelsberger, A., Mayershofer, R., Pech, O., Vashist, Y., Ott, K., Vieth, M., Weismüller, J., Nöthen, M. M., Attwood, S., Barr, H., Chegwidden, L., de Caestecker, J., Harrison, R., Love, S. B., MacDonald, D., Moayyedi, P., Prenen, H., Watson, R. G. P., Iyer, P. G., Anderson, L. A., Bernstein, L., Chow, W-H., Hardie, L. J., Lagergren, J., Liu, G., Risch, H. A., Wu, A. H., Ye, W., Bird, N. C., Shaheen, N. J., Gammon, M. D., Corley, D. A., Caldas, C., Moebus, S., Knapp, M., Peters, W. H. M., Neuhaus, H., Rösch, T., Ell, C., MacGregor, S., Pharoah, P., Whiteman, D. C., Jankowski, J., Schumacher, J. & Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), 10.2016, In: LANCET ONCOL. 17, 10, p. 1363-1373 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia Treatment: a Delphi consensus
Schmiegelow, K., Attarbaschi, A., Barzilai, S., Escherich, G., Frandsen, T. L., Halsey, C., Hough, R., Jeha, S., Kato, M., Liang, D-C., Mikkelsen, T. S., Möricke, A., Niinimäki, R., Piette, C., Putti, M. C., Raetz, E., Silverman, L. B., Skinner, R., Tuckuviene, R., van der Sluis, I., Zapotocka, E. & Ponte di Legno toxicity working group, 06.2016, In: LANCET ONCOL. 17, 6, p. e231-9Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup - a retrospective integrated clinical and molecular analysis
Thompson, E. M., Hielscher, T., Bouffet, E., Remke, M., Luu, B., Gururangan, S., McLendon, R. E., Bigner, D. D., Lipp, E. S., Perreault, S., Cho, Y-J., Grant, G., Kim, S-K., Lee, J-Y., Rao, A. A. N., Giannini, C., Li, K. K. W., Ng, H-K., Yao, Y., Kumabe, T., Tominaga, T., Grajkowska, W. A., Perek-Polnik, M., Low, D. C. Y., Seow, W. T., Chang, K. T. E., Mora, J., Pollack, I. F., Hamilton, R. L., Leary, S., Moore, A. S., Ingram, W. J., Hallahan, A. R., Jouvet, A., Fèvre-Montange, M., Vasiljevic, A., Faure-Conter, C., Shofuda, T., Kagawa, N., Hashimoto, N., Jabado, N., Weil, A. G., Gayden, T., Wataya, T., Shalaby, T., Grotzer, M., Zitterbart, K., Sterba, J., Kren, L., Hortobágyi, T., Klekner, A., László, B., Pócza, T., Hauser, P., Schüller, U., Jung, S., Jang, W-Y., French, P. J., Kros, J. M., van Veelen, M-L. C., Massimi, L., Leonard, J. R., Rubin, J. B., Vibhakar, R., Chambless, L. B., Cooper, M. K., Thompson, R. C., Faria, C. C., Carvalho, A., Nunes, S., Pimentel, J., Fan, X., Muraszko, K. M., López-Aguilar, E., Lyden, D., Garzia, L., Shih, D. J. H., Kijima, N., Schneider-Fresenius, C., Adamski, J., Northcott, P. A., Kool, M., Jones, D. T. W., Chan, J. A., Nikolic, A., Garre, M-L., Van Meir, E. G., Osuka, S., Olson, J. J., Jahangiri, A., Castro, B. A., Gupta, N., Weiss, W. A., Moxon-Emre, I., Mabbott, D. J., Lassaletta, A., Hawkins, C. E., Tabori, U., Drake, J., Kulkarni, A., Dirks, P. B., Rutka, J. T., Korshunov, A., Pfister, S. M., Packer, R. J., Ramaswamy, V. & Taylor, M. D., 04.2016, In: LANCET ONCOL. 17, 4, p. 484-95 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A., Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S., Chng, W-J. & ENDEAVOR Investigators, 01.2016, In: LANCET ONCOL. 17, 1, p. 27-38 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium, 01.2016, In: LANCET ONCOL. 17, 1, p. 78-89 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2015
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C. A., Killing, B., Depenbusch, R., Steffens, C-C., Al-Batran, S-E., Lange, T., Dietrich, G., Stoehlmacher, J., Tannapfel, A., Reinacher-Schick, A., Quidde, J., Trarbach, T., Hinke, A., Schmoll, H-J. & Arnold, D., 08.09.2015, In: LANCET ONCOL. 16, 13, p. 1355-69 15 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Zhu, A. X., Park, J. O., Ryoo, B-Y., Yen, C-J., Poon, R., Pastorelli, D., Blanc, J-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., Okusaka, T., Kubackova, K., Trojan, J., Sastre, J., Chau, I., Chang, S-C., Abada, P. B., Yang, L., Schwartz, J. D., Kudo, M. & REACH Trial Investigators, 07.2015, In: LANCET ONCOL. 16, 7, p. 859-70 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1):an open-label, randomised phase 3 trial
Machiels, J-P. H., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Vermorken, J. B., Clement, P. M., Gauler, T., Cupissol, D., Grau, J. J., Guigay, J., Caponigro, F., de Castro, G., de Souza Viana, L., Keilholz, U., Del Campo, J. M., Cong, X. J., Ehrnrooth, E., Cohen, E. E. W. & LUX-H&N 1 investigators, 05.2015, In: LANCET ONCOL. 16, 5, p. 583-94 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis
Torchia, J., Picard, D., Lafay-Cousin, L., Hawkins, C. E., Kim, S-K., Letourneau, L., Ra, Y-S., Ho, K. C., Chan, T. S. Y., Sin-Chan, P., Dunham, C. P., Yip, S., Ng, H-K., Lu, J-Q., Albrecht, S., Pimentel, J., Chan, J. A., Somers, G. R., Zielenska, M., Faria, C. C., Roque, L., Baskin, B., Birks, D., Foreman, N., Strother, D., Klekner, A., Garami, M., Hauser, P., Hortobágyi, T., Bognár, L., Wilson, B., Hukin, J., Carret, A-S., Van Meter, T. E., Nakamura, H., Toledano, H., Fried, I., Fults, D., Wataya, T., Fryer, C., Eisenstat, D. D., Scheineman, K., Johnston, D., Michaud, J., Zelcer, S., Hammond, R., Ramsay, D. A., Fleming, A. J., Lulla, R. R., Fangusaro, J. R., Sirachainan, N., Larbcharoensub, N., Hongeng, S., Barakzai, M. A., Montpetit, A., Stephens, D., Grundy, R. G., Schüller, U., Nicolaides, T., Tihan, T., Phillips, J., Taylor, M. D., Rutka, J. T., Dirks, P., Bader, G. D., Warmuth-Metz, M., Rutkowski, S., Pietsch, T., Judkins, A. R., Jabado, N., Bouffet, E. & Huang, A., 05.2015, In: LANCET ONCOL. 16, 5, p. 569-82 14 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., Mahner, S., Plante, M., Schmalfeldt, B., Mackay, H., Rowbottom, J., Lowe, E. S., Dougherty, B., Barrett, J. C. & Friedlander, M., 01.2015, In: LANCET ONCOL. 16, 1, p. 87-97 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2014
Surgery or topical therapy for vulval intraepithelial neoplasia
Mahner, S. & Wölber, L., 01.11.2014, In: LANCET ONCOL. 15, 12, p. 1287-1288 2 p.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data: a pooled analysis of individual patient data
Bidard, F-C., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Generali, D., Garcia-Saenz, J. A., Stebbing, J., Caldas, C., Gazzaniga, P., Manso, L., Zamarchi, R., de Lascoiti, A. F., De Mattos-Arruda, L., Ignatiadis, M., Lebofsky, R., van Laere, S. J., Meier-Stiegen, F., Sandri, M-T., Vidal-Martinez, J., Politaki, E., Consoli, F., Bottini, A., Diaz-Rubio, E., Krell, J., Dawson, S-J., Raimondi, C., Rutten, A., Janni, W., Munzone, E., Carañana, V., Agelaki, S., Almici, C., Dirix, L., Solomayer, E-F., Zorzino, L., Johannes, H., Reis-Filho, J. S., Pantel, K., Pierga, J-Y. & Michiels, S., 01.04.2014, In: LANCET ONCOL. 15, 4, p. 406-414 9 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Quality of life as a primary endpoint in ovarian cancer trials
Mahner, S. & Burges, A., 01.04.2014, In: LANCET ONCOL. 15, 4, p. 363-364 2 p.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
- 2013
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis
Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y-J., Shih, D. J. H., Luu, B., Dubuc, A. M., Northcott, P. A., Schüller, U., Gururangan, S., McLendon, R. E., Bigner, D. D., Fouladi, M., Ligon, K. L., Pomeroy, S. L., Dunn, S. E., Triscott, J., Jabado, N., Fontebasso, A., Jones, D. T. W., Kool, M., Karajannis, M. A., Gardner, S. L., Zagzag, D., Nunes, S., Pimentel, J., Mora, J., Lipp, E. S., Walter, A. W., Ryzhova, M., Zheludkova, O., Kumirova, E., Alshami, J., Croul, S. E., Rutka, J. T., Hawkins, C., Tabori, U., Codispoti, K-E. T., Packer, R. J., Pfister, S. M., Korshunov, A. & Taylor, M. D., 11.2013, In: LANCET ONCOL. 14, 12, p. 1200-7 8 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Miguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez-Lopez, J., Belch, A., Palumbo, A., Schey, S., Sonneveld, P., Yu, X., Sternas, L., Jacques, C., Zaki, M. & Dimopoulos, M., 10.2013, In: LANCET ONCOL. 14, 11, p. 1055-1066 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review